

The first example of fluoro-Meinwald rearrangement

**Savva A. Ponomarev, Roman V. Larkovich, Alexander S. Aldoshin,
Victor N. Khrustalev and Valentine G. Nenajdenko**

Table of contents

Experimental data	S1
NMR spectra of compounds obtained	S7

Experimental data

All reagents were purchased from commercial sources and used without any further purification. All solvents were dried before use by the standard procedures [D. B. G. Williams, M. Lawton, *J. Org. Chem.* 2010, **75**, 8351–8354]. Melting points (M.p.) were measured with a Büchi B-545 melting point apparatus. NMR (¹H, ¹³C and ¹⁹F) spectra were registered in deuterated chloroform (CDCl₃) with Bruker AV-400 and Agilent 400-MR spectrometers. Chemical shifts for ¹H NMR spectroscopic data were referenced to internal tetramethylsilane (δ = 0.0 ppm) and the residual solvent resonance (δ = 7.26 ppm). Chemical shifts for ¹³C NMR spectroscopic data were referenced to the residual solvent resonance (δ = 77.16 ppm). Chemical shifts for ¹⁹F NMR spectroscopic data were referenced to PhCF₃ (δ = −63.72 ppm) added as a standard. Data are reported as follows: chemical shift, integration multiplicity (s = singlet, d = doublet, t = triplet, q = quadruplet, qui = quintet, sext = sextet, sept = septet, br = broad, m = multiplet, dd = *doublet of doublets*, ddd = *doublet of doublet of doublets*, ddt = *doublet of doublet of triplets*) and coupling constants (Hz). The starting 6-aryl-5-fluoro-5-nitro bicyclo[2.2.1]hept-2-enes **2** and 6-(2,4-dichlorophenyl)-5-fluoro-5-nitro bicyclo[2.2.2]oct-2-ene **7** were prepared as mixture of *exo*- and *endo*-isomers according to the described procedure and are the known compounds [S. A. Ponomarev, R. V. Larkovich, A. S. Aldoshin, A. A. Tabolin, S. L. Ioffe, J. Groß, T. Opatz and V. G. Nenajdenko, *Beilstein J. Org. Chem.* 2021, **17**, 283].

General procedure for base-induced HNO₂-elimination from (4+2)-cycloadducts

In a typical experiment, a solution of a selected cycloadduct **2** or **7** (0.2 mmol, 1 mol. equiv.) in THF (1 mL) was loaded into a vial covered with aluminum foil. Then, potassium *tert*-butoxide (2–4 mol. equiv.) was added in several portions over 20 min to the vigorously stirred reaction mixture in the

dark. The reaction mixture was stirred overnight at room temperature (TLC monitoring). After completion of the reaction, the mixture was passed through a layer of neutral alumina charged into a column covered with an aluminum foil using DCM as eluent. The solution of pure product **2** was collected into a flask covered with aluminum foil and then concentrated under vacuum.

2-(4-Chlorophenyl)-3-fluorobicyclo[2.2.1]hepta-2,5-diene (2a). 73 mg (89%); colorless oil. ^1H NMR (400 MHz, CDCl_3): δ = 2.17 – 2.25 (m, 1H), 2.39 (d, J = 6.1 Hz, 1H), 3.42 – 3.47 (m, 1H), 3.79 – 3.85 (m, 1H), 6.91 – 6.96 (m, 1H), 7.00 – 7.04 (m, 1H), 7.27 – 7.32 (m, 2H), 7.32 – 7.37 (m, 2H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ = 49.7 (d, $^3J_{\text{CF}}$ = 5.0 Hz), 50.9 (d, $^2J_{\text{CF}}$ = 20.5 Hz), 69.6 (d, $^3J_{\text{CF}}$ = 5.9 Hz), 122.4 (d, $^2J_{\text{CF}}$ = 1.5 Hz), 126.7 (d, $^4J_{\text{CF}}$ = 6.3 Hz), 128.7, 131.8 (d, $^3J_{\text{CF}}$ = 5.4 Hz), 131.9 (d, $^6J_{\text{CF}}$ = 3.8 Hz), 141.5 (d, $^4J_{\text{CF}}$ = 4.2 Hz), 143.3 (d, $^3J_{\text{CF}}$ = 6.0 Hz), 175.0 (d, $^1J_{\text{CF}}$ = 303.9 Hz) ppm; ^{19}F NMR (376 MHz, CDCl_3): δ = -119.22 – -119.15 (m) ppm.

2-(4-Bromophenyl)-3-fluorobicyclo[2.2.1]hepta-2,5-diene (2b). 45 mg (91%); colorless oil. ^1H NMR (400 MHz, CDCl_3): δ = 2.17 – 2.24 (m, 1H), 2.35 – 2.42 (m, 1H), 3.44 (s, 1H), 3.82 (s, 1H), 6.90 – 6.96 (m, 1H), 6.98 – 7.05 (m, 1H), 7.24 – 7.32 (m, 2H), 7.41 – 7.50 (m, 2H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ = 49.6 (d, $^3J_{\text{CF}}$ = 4.8 Hz), 50.9 (d, $^2J_{\text{CF}}$ = 20.5 Hz), 69.5 (d, $^3J_{\text{CF}}$ = 5.8 Hz), 120.0 (d, $^6J_{\text{CF}}$ = 3.5 Hz), 122.5 (d, $^2J_{\text{CF}}$ = 1.8 Hz), 127.1 (d, $^4J_{\text{CF}}$ = 6.1 Hz), 131.7, 132.3 (d, $^3J_{\text{CF}}$ = 5.2 Hz), 141.5 (d, $^4J_{\text{CF}}$ = 4.2 Hz), 143.3 (d, $^3J_{\text{CF}}$ = 5.9 Hz), 175.1 (d, $^1J_{\text{CF}}$ = 304.4 Hz) ppm; ^{19}F NMR (376 MHz, CDCl_3): δ = -118.74 – -118.69 (m) ppm.

2-Fluoro-3-phenylbicyclo[2.2.1]hepta-2,5-diene (2c). 155 mg (81%); colorless oil. ^1H NMR (400 MHz, CDCl_3): δ = 2.21 (ddd, J = 7.8, 3.4, 1.9 Hz, 1H), 2.40 (d, J = 6.1 Hz, 1H), 3.49 – 3.40 (m, 1H), 3.92 – 3.83 (m, 1H), 6.94 (dd, J = 4.7, 3.0 Hz, 1H), 7.04 (dt, J = 4.6, 2.1 Hz, 1H), 7.19 (t, J = 7.3 Hz, 1H), 7.35 (t, J = 7.8 Hz, 2H), 7.46 – 7.41 (m, 2H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ = 49.7 (d, $^3J_{\text{CF}}$ = 5.1 Hz), 50.8 (d, $^2J_{\text{CF}}$ = 20.7 Hz), 69.5 (d, $^3J_{\text{CF}}$ = 5.9 Hz), 123.2 (d, $^2J_{\text{CF}}$ = 1.5 Hz), 125.5 (d, $^4J_{\text{CF}}$ = 6.0 Hz), 126.4 (d, $^6J_{\text{CF}}$ = 2.2 Hz), 128.6, 133.4 (d, $^3J_{\text{CF}}$ = 5.0 Hz), 141.5 (d, $^4J_{\text{CF}}$ = 4.1 Hz), 143.5 (d, $^3J_{\text{CF}}$ = 6.0 Hz), 174.6 (d, $^1J_{\text{CF}}$ = 302.9 Hz) ppm; ^{19}F NMR (376 MHz, CDCl_3): δ = -120.52 – -120.46 (m) ppm.

2-(4-*tert*-Butylphenyl)-3-fluorobicyclo[2.2.1]hepta-2,5-diene (2d). 101 mg (78%); yellow oil. ^1H NMR (400 MHz, CDCl_3): δ = 1.32 (s, 9H), 2.16 – 2.22 (m, 1H), 2.37 (dt, J = 6.0, 1.4 Hz, 1H), 3.40 – 3.45 (m, 1H), 3.83 – 3.89 (m, 1H), 6.89 – 6.94 (m, 1H), 7.01 (dt, J = 4.6, 2.1 Hz, 1H), 7.38 (s, 4H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ = 31.4, 34.6, 49.7 (d, $^3J_{\text{CF}}$ = 5.2 Hz), 50.8 (d, $^2J_{\text{CF}}$ = 20.7 Hz), 69.5 (d, $^3J_{\text{CF}}$ = 5.9 Hz), 123.0 (d, $^2J_{\text{CF}}$ = 1.8 Hz), 125.2 (d, $^4J_{\text{CF}}$ = 5.8 Hz), 125.5, 130.6 (d, $^3J_{\text{CF}}$ = 5.1 Hz), 141.4 (d, $^4J_{\text{CF}}$ = 4.1 Hz), 143.4 (d, $^3J_{\text{CF}}$ = 6.0 Hz), 149.3 (d, $^6J_{\text{CF}}$ = 2.2 Hz), 174.0 (d, $^1J_{\text{CF}}$ = 301.7 Hz) ppm; ^{19}F NMR (376 MHz, CDCl_3): δ = -121.73 – -121.64 (m) ppm.

2-(2,4-Dichlorophenyl)-3-fluorobicyclo[2.2.1]hepta-2,5-diene (2e). 80 mg (95%); pale yellow oil. ¹H NMR (400 MHz, CDCl₃): δ = 2.19 – 2.25 (m, 1H), 2.50 (dt, J = 6.1, 1.6 Hz, 1H), 3.38 – 3.44 (m, 1H), 3.80 – 3.86 (m, 1H), 6.92 – 6.98 (m, 1H), 7.06 – 7.10 (m, 1H), 7.11 (d, J = 8.3 Hz, 1H), 7.18 (dd, J = 8.4, 2.1 Hz, 1H), 7.37 (d, J = 2.1 Hz, 1H) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 50.3 (d, $^2J_{CF}$ = 20.3 Hz), 52.6 (d, $^3J_{CF}$ = 4.1 Hz), 71.1 (d, $^3J_{CF}$ = 5.2 Hz), 121.7 (d, $^2J_{CF}$ = 3.2 Hz), 127.0, 129.8, 130.4 (d, $^4J_{CF}$ = 3.2 Hz), 131.3 (d, $^3J_{CF}$ = 3.7 Hz), 133.0, 133.1 (d, $^4J_{CF}$ = 1.8 Hz), 141.0 (d, $^4J_{CF}$ = 3.8 Hz), 144.8 (d, $^3J_{CF}$ = 5.8 Hz), 176.1 (d, $^1J_{CF}$ = 303.4 Hz) ppm; ¹⁹F NMR (376 MHz, CDCl₃): δ = -118.73 – -118.66 (m) ppm.

2-Fluoro-3-(4-nitrophenyl)bicyclo[2.2.1]hepta-2,5-diene (2f). 34 mg (77%); yellow oil. ¹H NMR (400 MHz, CDCl₃): δ = 2.25 – 2.31 (m, 1H), 2.41 – 2.46 (m, 1H), 3.48 – 3.53 (m, 1H), 3.88 – 3.94 (m, 1H), 6.92 – 6.97 (m, 1H), 7.03 – 7.08 (m, 1H), 7.48 – 7.55 (m, 2H), 8.15 – 8.21 (m, 2H) ppm; ¹⁹F NMR (376 MHz, CDCl₃): δ = -110.34 (s) ppm. The analysis of the sample was consistent with the previously reported data [A. V. Shastin, V. G. Nenajdenko, V. M. Muzalevskiy, E. S. Balenkova, R. Fröhlich, G. Haufe, *Tetrahedron*, 2008, **64**, 9725].

2-(2,4-Dichlorophenyl)-3-fluorobicyclo[2.2.2]octa-2,5-diene (8). 37 mg (76%); yellowish oil. Anal. calcd. for C₁₄H₁₁Cl₂F (%): C, 62.48; H, 4.12; found C, 63.89; H, 4.46; ¹H NMR (400 MHz, CDCl₃): δ = 1.37 – 1.52 (m, 2H), 1.66 – 1.75 (m, 1H), 1.77 – 1.86 (m, 1H), 3.56 – 3.66 (m, 1H), 3.71 – 3.79 (m, 1H), 6.36 – 6.43 (m, 1H), 6.45 – 6.52 (m, 1H), 7.10 (dd, J = 8.3, 0.6 Hz, 1H), 7.18 (dd, J = 8.3, 2.1 Hz, 1H), 7.40 (d, J = 2.1 Hz, 1H) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 25.1 (d, $^3J_{CF}$ = 1.7 Hz), 25.9 (d, $^4J_{CF}$ = 1.0 Hz), 38.7 (d, $^2J_{CF}$ = 21.4 Hz), 41.6 (d, $^3J_{CF}$ = 2.2 Hz), 115.6 (d, $^2J_{CF}$ = 3.7 Hz), 126.9, 129.7, 131.8 (d, $^4J_{CF}$ = 2.3 Hz), 132.8 (d, $^3J_{CF}$ = 1.5 Hz), 132.9, 133.3, 134.0, 136.0 (d, $^3J_{CF}$ = 2.8 Hz), 162.7 (d, $^1J_{CF}$ = 285.7 Hz) ppm; ¹⁹F NMR (376 MHz, CDCl₃): δ = -114.80 – -114.66 (m) ppm.

Procedure for UV-irradiation of norbornadienes 2

In a typical experiment, a solution of norbornadiene **2** (0.2 mmol, 1 mol. equiv.) in dichloromethane (5 mL) was loaded into a quartz vial placed in an ice bath. The mixture was stirred for 6-7 hours under UV irradiation (254 nm, 6 W) until completion. The progress of the reaction was monitored by TLC and ¹⁹F NMR. After completion of the reaction, the mixture was concentrated under vacuum and then separated by column chromatography on silica using a hexane/dichloromethane (4:1) mixture as eluent. Thus, the target acyl fluoride **3** and ketone **4** as a side product were isolated as pure compounds.

(1S*,5R*,6R*)-6-(4-Chlorophenyl)bicyclo[3.1.0]hex-2-ene-6-carbonyl fluoride (3a). 26 mg (45%); colorless oil. IR (neat): 1829 (-C=O) cm⁻¹. ¹H NMR (400 MHz, CDCl₃, ¹H-¹³C HMBC, ¹H-

¹³C HSQC): δ = 2.26 (q, J = 6.4 Hz, 1H, H⁴), 2.71 – 2.82 (m, 2H, H^{3,5}), 2.89 – 2.98 (m, 1H, H⁵), 5.78 – 5.84 (m, 1H, H^{1,2}), 5.91 – 5.97 (m, 1H, H^{1,2}), 7.33 (s, 4H, H^{9,10,12,13}) ppm; ¹³C NMR (100 MHz, CDCl₃, ¹H-¹³C HMBC, ¹H-¹³C HSQC): δ = 30.9 (d, $^3J_{CF}$ = 1.5 Hz, C⁴), 34.5 (C⁵), 38.4 (d, $^2J_{CF}$ = 59.6 Hz, C⁶), 39.0 (d, $^3J_{CF}$ = 1.4 Hz, C³), 128.8 (C^{1,2}), 129.2 (C^{9,10,12,13}), 130.3 (C^{9,10,12,13}), 133.7 (C^{1,2}), 134.2 (C¹¹), 135.4 (d, $^3J_{CF}$ = 2.4 Hz, C⁷), 158.1 (d, $^1J_{CF}$ = 359.8 Hz, C⁸) ppm; ¹⁹F NMR (376 MHz, CDCl₃): δ = 46.48 (d, J_{HF} = 5.9 Hz) ppm.

(1*S*^{*,3*R*^{*,4*R*^{*}})-3-(4-Chlorophenyl)-3-hydroxybicyclo[2.2.1]hept-5-en-2-one (4a).} 11 mg (19%); colorless oil. HRMS (ESI): calcd. for C₁₃H₁₂³⁵ClO₂ [M+H]⁺ = 235.0520; found 235.0517. ¹H NMR (400 MHz, CDCl₃): δ = 2.13 (d, J = 9.4 Hz, 1H), 2.27 (d, J = 9.4 Hz, 1H), 3.27 (dd, J = 3.5, 1.4 Hz, 1H), 3.29 – 3.33 (m, 1H), 3.43 (d, J = 2.9 Hz, 1H), 6.17 (dd, J = 5.1, 3.5 Hz, 1H), 6.40 (dd, J = 5.1, 2.9 Hz, 1H), 7.09 (d, J = 8.4 Hz, 2H), 7.21 – 7.26 (m, 2H) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 46.3, 49.5, 51.8, 57.0, 128.5, 129.5, 129.6, 132.8, 138.2, 141.3, 211.8 ppm.

(1*S*^{*,5*R*^{*,6*R*^{*}})-6-(4-Bromophenyl)bicyclo[3.1.0]hex-2-ene-6-carbonyl fluoride (3b).} 24 mg (43%); colorless oil. ¹H NMR (400 MHz, CDCl₃): δ = 2.26 (q, J = 6.4 Hz, 1H), 2.70 – 2.82 (m, 2H), 2.88 – 2.98 (m, 1H), 5.78 – 5.85 (m, 1H), 5.90 – 5.97 (m, 1H), 7.27 (d, J = 8.3 Hz, 2H), 7.45 – 7.52 (m, 2H) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 30.9 (d, $^3J_{CF}$ = 1.9 Hz), 34.5, 38.4 (d, $^2J_{CF}$ = 59.5 Hz), 39.0 (d, $^3J_{CF}$ = 1.4 Hz), 122.3, 128.7, 130.6, 132.1, 133.8, 135.9 (d, $^3J_{CF}$ = 2.7 Hz), 158.0 (d, $^1J_{CF}$ = 359.8 Hz) ppm; ¹⁹F NMR (376 MHz, CDCl₃): δ = 46.57 (d, J_{HF} = 5.9 Hz) ppm.

(1*S*^{*,3*R*^{*,4*R*^{*}})-3-(4-Bromophenyl)-3-hydroxybicyclo[2.2.1]hept-5-en-2-one (4b).} 10 mg (18%); colorless oil. HRMS (ESI): calcd. for C₁₃H₁₂⁷⁹BrO₂ [M+H]⁺ = 279.0015; found 279.0011. ¹H NMR (400 MHz, CDCl₃): δ = 2.13 (d, J = 9.3 Hz, 1H), 2.27 (d, J = 9.3 Hz, 1H), 3.25 – 3.29 (m, 1H), 3.29 – 3.35 (m, 1H), 3.41 (d, J = 3.0 Hz, 1H), 6.13 – 6.19 (m, 1H), 6.39 (dd, J = 5.4, 2.6 Hz, 1H), 7.03 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 46.3, 49.5, 51.8, 57.0, 120.9, 129.7, 129.9, 131.5, 138.7, 141.3, 211.7 ppm.

(1*S*^{*,5*R*^{*,6*R*^{*}})-6-Phenylbicyclo[3.1.0]hex-2-ene-6-carbonyl fluoride (3c).} 25 mg (30%); colorless oil. HRMS (ESI): calcd. for C₁₃H₁₁FNaO [M+Na]⁺ 225.0686; found 225.0685. ¹H NMR (400 MHz, CDCl₃) δ 2.29 (q, J = 6.3 Hz, 1H), 2.71 – 2.84 (m, 2H), 2.88 – 3.01 (m, 1H), 5.78 – 5.84 (m, 1H), 5.93 – 5.99 (m, 1H), 7.27 – 7.43 (m, 5H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 30.8 (d, $^3J_{CF}$ = 1.8 Hz), 34.5, 38.8 (d, $^3J_{CF}$ = 1.4 Hz), 39.1 (d, $^2J_{CF}$ = 59.0 Hz), 128.2, 128.8, 129.0, 129.1, 133.4, 136.9 (d, $^3J_{CF}$ = 2.5 Hz), 158.5 (d, $^1J_{CF}$ = 359.9 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃) δ 46.33 (d, J_{HF} = 6.1 Hz) ppm.

Procedure for hydrolysis of acyl fluorides 3

An aqueous solution of 1 M NaOH (10 mL) was added to acyl fluoride **3** (0.12-0.17 mmol). The mixture was stirred at room temperature for 15 h (TLC monitoring). After completion of the reaction, the mixture was poured into an aqueous solution of 5% HCl (25 mL) and then extracted with dichloromethane. The combined organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under vacuum. The pure product **5** was isolated by column chromatography on silica gel using a hexane/ethyl acetate (2:1) mixture as eluent.

(1*S,*5R**,*6R**)-6-(4-Chlorophenyl)bicyclo[3.1.0]hex-2-ene-6-carboxylic acid (5a).** 36 mg (90%); colorless solid. M.p. 137-139 °C. HRMS (ESI): calcd. for C₁₃H₁₂³⁵ClO₂ [M+H]⁺ = 235.0520; found 235.0513. ¹H NMR (400 MHz, CDCl₃): δ = 2.11 (t, *J* = 6.7 Hz, 1H), 2.53 – 2.61 (m, 1H), 2.62 – 2.73 (dd, *J* = 18.3, 7.0 Hz, 1H), 2.89 (dd, *J* = 18.4, 1.9 Hz, 1H), 5.62 – 5.68 (m, 1H), 5.89 (dd, *J* = 5.4, 2.1 Hz, 1H), 7.26 – 7.30 (m, 2H), 7.32 – 7.38 (m, 2H) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 29.9, 34.4, 37.9, 40.0, 128.8, 130.1, 130.4, 132.2, 133.5, 137.7, 175.0 ppm.

(1*S,*5R**,*6R**)-6-(4-Bromophenyl)bicyclo[3.1.0]hex-2-ene-6-carboxylic acid (5b).** 30 mg (93%); colorless solid. M.p. 143-145°C. HRMS (ESI): calcd. for C₁₃H₁₂BrO₂ [M+H]⁺ = 279.0015; found 279.0018. ¹H NMR (400 MHz, CDCl₃): δ = 2.15 (t, *J* = 6.7 Hz, 1H), 2.55 – 2.60 (m, 1H), 2.62 – 2.73 (m, 1H), 2.84 – 2.95 (m, 1H), 5.63 – 5.69 (m, 1H), 5.90 (dd, *J* = 5.4, 2.1 Hz, 1H), 7.27 – 7.32 (m, 2H), 7.40 – 7.47 (m, 2H) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 29.9, 34.4, 37.8, 40.0, 121.6, 130.1, 130.7, 131.8, 132.3, 138.3, 173.6 ppm.

Procedure for preparation of amides 6

Pyrrolidine (0.08-0.1 mmol, 2 mol. equiv.) was added to a solution of acyl fluoride **3** (0.04-0.05 mmol, 1 mol. equiv.) in dichloromethane (1-1.2 mL). The mixture was stirred at room temperature for 5 min (TLC monitoring). After completion of the reaction, the mixture was extracted with an aqueous solution of 5% HCl (15 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under vacuum. The pure product **6** was isolated by column chromatography on silica gel using a hexane/ethyl acetate (2:1) mixture as eluent.

((1*S,*5R**,*6R**)-6-(4-Chlorophenyl)bicyclo[3.1.0]hex-2-en-6-yl)(pyrrolidin-1-yl)methanone (6a).** 13 mg (89%); colorless oil. HRMS (ESI): calcd. for C₁₇H₁₉ClNO [M+H]⁺ = 288.1150; found 288.1152. ¹H NMR (400 MHz, CDCl₃): δ = 1.67 – 1.85 (m, 4H), 1.92 – 2.05 (m, 1H), 2.60 – 2.74 (m, 2H), 3.01 (d, *J* = 17.1 Hz, 1H), 3.10 – 3.21 (m, 1H), 3.21 – 3.31 (m, 1H), 3.31 – 3.41 (m, 1H), 3.42 – 3.53 (m, 1H), 5.66 – 5.73 (m, 1H), 5.81 – 5.88 (m, 1H), 7.06 (d, *J* = 8.6 Hz, 2H), 7.23 (d, *J* = 8.6 Hz,

2H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ = 24.2, 26.2, 31.1, 34.6, 35.6, 39.3, 45.7, 46.8, 126.9, 128.2, 128.8, 132.0, 133.7, 139.3, 166.9 ppm.

((1*S,5*R**,6*R**)-6-(4-Bromophenyl)bicyclo[3.1.0]hex-2-en-6-yl)(pyrrolidin-1-yl)methanone (6b).** 13 mg (95%); colorless oil. HRMS (ESI): calcd. for $\text{C}_{17}\text{H}_{19}\text{BrNO}$ $[\text{M}+\text{H}]^+$ = 332.0645; found 332.0650. ^1H NMR (400 MHz, CDCl_3): δ = 1.69 – 1.85 (m, 4H), 1.93 – 2.06 (m, 1H), 2.58 – 2.76 (m, 2H), 2.93 – 3.09 (m, 1H), 3.11 – 3.21 (m, 1H), 3.22 – 3.31 (m, 1H), 3.31 – 3.42 (m, 1H), 3.43 – 3.54 (m, 1H), 5.67 – 5.74 (m, 1H), 5.81 – 5.88 (m, 1H), 6.97 – 7.04 (m, 2H), 7.35 – 7.42 (m, 2H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ = 24.3, 26.2, 29.8, 34.7, 35.7, 39.3, 45.7, 46.8, 120.1, 127.3, 128.1, 131.7, 133.8, 139.9, 166.8 ppm.

Table S1 Optimization of the reaction conditions for synthesis of norbornadienes **2^a**

#	Substrate	T °C	Base	Conv. ^b %	Yield ^b %
1	1a	65 ^c	DBU (4 eq)	40	34
2	1a	rt	Bu ^t OK (1 eq)	28	25
3	1a	rt	Bu ^t OK (2 eq)	64	60
4	1a	rt	Bu ^t OK (3 eq)	79	72
<u>5</u>	<u>1a</u>	<u>rt</u>	<u>Bu^tOK (4 eq)</u>	<u>100</u>	<u>100 (89)^d</u>
6	1f	rt	DBU (4 eq)	100	0
7	1f	rt	Bu ^t OK (1.1 eq)	80	80
<u>8</u>	<u>1f</u>	<u>rt</u>	<u>Bu^tOK (2 eq)</u>	<u>100</u>	<u>77^d</u>
9	1f	rt	Bu ^t OK (4 eq)	100	trace


(a) – reaction conditions: 0.2 mmol of **1** in THF (1 ml); overnight

(b) – calculated via ^{19}F NMR spectra using $\text{CF}_3\text{C}_6\text{H}_5$ as an internal standard

(c) – reaction time 15h


(d) – isolated by flash column chromatography on neutral Al_2O_3

PSA-77.H
chloroform-d





^1H NMR spectrum of 2-(4-chlorophenyl)-3-fluorobicyclo[2.2.1]hepta-2,5-diene (**2a**)

PSA-78.C
chloroform-d




^{13}C NMR spectrum of 2-(4-chlorophenyl)-3-fluorobicyclo[2.2.1]hepta-2,5-diene (**2a**)

PSA-77.F
chloroform-d




¹⁹F NMR spectrum of 2-(4-chlorophenyl)-3-fluorobicyclo[2.2.1]hepta-2,5-diene (**2a**)

PSA-82.H
chloroform-d





^1H NMR spectrum of 2-(4-bromophenyl)-3-fluorobicyclo[2.2.1]hepta-2,5-diene (**2b**)




¹³C NMR spectrum of 2-(4-bromophenyl)-3-fluorobicyclo[2.2.1]hepta-2,5-diene (**2b**)

PSA-82.F
chloroform-d




^{19}F NMR spectrum of 2-(4-bromophenyl)-3-fluorobicyclo[2.2.1]hepta-2,5-diene (**2b**)

PSA-71-8.H
chloroform-d





^1H NMR spectrum of 2-fluoro-3-phenylbicyclo[2.2.1]hepta-2,5-diene (**2c**)

PSA-71-8.C
chloroform-d




¹³C NMR spectrum of 2-fluoro-3-phenylbicyclo[2.2.1]hepta-2,5-diene (**2c**)

PSA-71-8.F
chloroform-d




^{19}F NMR spectrum of 2-fluoro-3-phenylbicyclo[2.2.1]hepta-2,5-diene (**2c**)

PSA-71-5.H
chloroform-d





^1H NMR spectrum of 2-(4-*tert*-butylphenyl)-3-fluorobicyclo[2.2.1]hepta-2,5-diene (**2d**)

PSA-71-5.C
chloroform-d




^{13}C NMR spectrum of 2-(4-tert-butylphenyl)-3-fluorobicyclo[2.2.1]hepta-2,5-diene (**2d**)


PSA-71-5.F
chloroform-d



PSA-45.1.H
chloroform-d




^1H NMR spectrum of 2-(2,4-dichlorophenyl)-3-fluorobicyclo[2.2.1]hepta-2,5-diene (**2e**)



¹³C NMR spectrum of 2-(2,4-dichlorophenyl)-3-fluorobicyclo[2.2.1]hepta-2,5-diene (**2e**)

PSA-71-3.F
chloroform-d




— -63.72

— -118.69
— -118.69
— -118.70


— -118.69
— -118.69
— -118.70

standard





¹⁹F NMR spectrum of 2-(2,4-dichlorophenyl)-3-fluorobicyclo[2.2.1]hepta-2,5-diene (**2e**)

PSA-42.H
chloroform-d




¹H NMR spectrum of 2-fluoro-3-(4-nitrophenyl)bicyclo[2.2.1]hepta-2,5-diene (**2f**)


PSA-42.F
chloroform-d



^{19}F NMR spectrum of 2-fluoro-3-(4-nitrophenyl)bicyclo[2.2.1]hepta-2,5-diene (**2f**)





¹H NMR spectrum of 2-(2,4-dichlorophenyl)-3-fluorobicyclo[2.2.2]octa-2,5-diene (**8**)




¹³C NMR spectrum of 2-(2,4-dichlorophenyl)-3-fluorobicyclo[2.2.2]octa-2,5-diene (**8**)

LRV-93.F
chloroform-d




^{19}F NMR spectrum of 2-(2,4-dichlorophenyl)-3-fluorobicyclo[2.2.2]octa-2,5-diene (**8**)

PSA-86-COF.H
chloroform-d




^1H NMR spectrum of $(1\text{S}^*, 5\text{R}^*, 6\text{R}^*)$ -6-(4-chlorophenyl)bicyclo[3.1.0]hex-2-ene-6-carbonyl fluoride (**3a**)




¹³C NMR spectrum of (1*S**,5*R**,6*R**)-6-(4-chlorophenyl)bicyclo[3.1.0]hex-2-ene-6-carbonyl fluoride (**3a**)

PSA-86-COF, APT
chloroform-d
— 159.87
— 156.29


135.36
135.33
134.17
133.72
130.32
129.15
128.74




38.98
38.97
38.64
38.05
34.49
30.86
30.84



¹³C APT NMR spectrum of (1S*,5R*,6R*)-6-(4-chlorophenyl)bicyclo[3.1.0]hex-2-ene-6-carbonyl fluoride (**3a**)



^1H - ^{13}C HMBC spectrum of $(1S^*,5R^*,6R^*)$ -6-(4-chlorophenyl)bicyclo[3.1.0]hex-2-ene-6-carbonyl fluoride (**3a**)





^1H - ^{13}C HSQC spectrum of ($1S^*, 5R^*, 6R^*$)-6-(4-chlorophenyl)bicyclo[3.1.0]hex-2-ene-6-carbonyl fluoride (**3a**)


PSA-77.2fr.F
chloroform-d

46.49
46.47


-63.72




^{19}F NMR spectrum of $(1\text{S}^*, 5\text{R}^*, 6\text{R}^*)$ -6-(4-chlorophenyl)bicyclo[3.1.0]hex-2-ene-6-carbonyl fluoride (**3a**)



PSA-126.H
chloroform-d



¹H NMR spectrum of (1S*,5R*,6R*)-6-(4-bromophenyl)bicyclo[3.1.0]hex-2-ene-6-carbonyl fluoride (**3b**)




¹³C NMR spectrum of (1*S*^{*,}5*R*^{*,}6*R*^{*)}-6-(4-bromophenyl)bicyclo[3.1.0]hex-2-ene-6-carbonyl fluoride (**3b**)



PSA-126.F
chloroform-d

46.58
< 46.57


-63.72



46.58
< 46.57




¹⁹F NMR spectrum of (1*S**,5*R**,6*R**)-6-(4-bromophenyl)bicyclo[3.1.0]hex-2-ene-6-carbonyl fluoride (**3b**)




^1H NMR spectrum of ($1\text{S}^*,5\text{R}^*,6\text{R}^*$)-6-phenylbicyclo[3.1.0]hex-2-ene-6-carbonyl fluoride (**3c**)

AAS-3.212.OX.1.1fr.C
chloroform-d




^{13}C NMR spectrum of $(1\text{S}^*, 5\text{R}^*, 6\text{R}^*)$ -6-phenylbicyclo[3.1.0]hex-2-ene-6-carbonyl fluoride (**3c**)

AAS-3.212.OX.1.1fr.F
chloroform-d





46.34
46.33

-63.72




¹⁹F NMR spectrum of (1S*,5R*,6R*)-6-phenylbicyclo[3.1.0]hex-2-ene-6-carbonyl fluoride (**3c**)

PSA-325-KET.H
chloroform-d





¹H NMR spectrum of (1*S*^{*,}3*R*^{*,}4*R*^{*)}-3-(4-chlorophenyl)-3-hydroxybicyclo[2.2.1]hept-5-en-2-one (**4a**)

PSA-325-KET.C
chloroform-d 34




¹³C NMR spectrum of (1*S*^{*},3*R*^{*},4*R*^{*})-3-(4-chlorophenyl)-3-hydroxybicyclo[2.2.1]hept-5-en-2-one (**4a**)

PSA-232-F3.H
chloroform-d





¹H NMR spectrum of (1S*,3R*,4R*)-3-(4-bromophenyl)-3-hydroxybicyclo[2.2.1]hept-5-en-2-one (**4b**)

PSA-232-F3.C
chloroform-d



¹³C NMR spectrum of (1S*,3R*,4R*)-3-(4-bromophenyl)-3-hydroxybicyclo[2.2.1]hept-5-en-2-one (**4b**)


PSA-97.H
chloroform-d




PSA-97.C
chloroform-d

— 174.97

137.72
133.47
132.22
130.43
130.12
128.82





~ 40.02
~ 37.86
~ 34.40
~ 29.85



¹³C NMR spectrum of (1S*,5R*,6R*)-6-(4-chlorophenyl)bicyclo[3.1.0]hex-2-ene-6-carboxylic acid (**5a**)

PSA-Br-AC.H
chloroform-d




¹H NMR spectrum of (1*S*^{*,5*R*^{*,6*R*^{*}}})-6-(4-bromophenyl)bicyclo[3.1.0]hex-2-ene-6-carboxylic acid (**5b**)


!PSA-Br-AC.C
chloroform-d

— 173.62

✓ 138.31
✓ 132.27
✓ 131.79
✓ 130.68
✓ 130.13
— 121.58





✓ 39.97
✓ 37.84
✓ 34.44
✓ 29.94





¹³C NMR spectrum of (1S*,5R*,6R*)-6-(4-bromophenyl)bicyclo[3.1.0]hex-2-ene-6-carboxylic acid (**5b**)



PSA-4-Cl-AM.H
chloroform-d





¹H NMR spectrum of ((1S*,5R*,6R*)-6-(4-chlorophenyl)bicyclo[3.1.0]hex-2-en-6-yl)(pyrrolidin-1-yl)methanone (**6a**)



PSA-Br-AM.H
chloroform-d



¹H NMR spectrum of ((1S*,5R*,6R*)-6-(4-bromophenyl)bicyclo[3.1.0]hex-2-en-6-yl)(pyrrolidin-1-yl)methanone (**6b**)



^{13}C NMR spectrum of ((1*S*^{*,5*R*^{*,6*R*^{*}}})-6-(4-bromophenyl)bicyclo[3.1.0]hex-2-en-6-yl)(pyrrolidin-1-yl)methanone (**6b**)